Thanks Hitesh for a lucid explanation of the impact of the latest approval.
The market seems to be considering abilify as an one time earning. Now another big approval in their fold the earnings should grow more homogeneous way.
Only thing left now is their own front end team in US, which they are already building. So their margins will improve going forward. This will ensure that the lumpiness in earnings due to the nature of generic business will reduce to certain extent.
| Subscribe To Our Free Newsletter |
